de Almeida Marcelino, Ana Luísa http://orcid.org/0000-0002-3291-7222
Mainka, Tina http://orcid.org/0000-0002-0597-2648
Krause, Patricia http://orcid.org/0000-0001-9063-0556
Poewe, Werner http://orcid.org/0000-0003-4367-0971
Ganos, Christos http://orcid.org/0000-0001-8077-8530
Kühn, Andrea A.
Article History
Received: 8 April 2020
Revised: 25 April 2020
Accepted: 28 April 2020
First Online: 9 July 2020
Compliance with ethical standards
:
: There are no conflicts of interest to declare regarding funding/sponsoring of this manuscript from any of the authors. Independently from the submitted work: ALAM has no conflicts of interest to declare. TM receives royalties from Urban Fischer in Elsevier Verlag. TM is a participant in the BIH-Charité Clinician Scientist Program funded by the Charité-Universitätsmedizin Berlin and the Berlin Institute of Health. PK received speaker´s honoraria from Medtronic. WP reports personal fees from AbbVie, Affiris, AstraZeneca, BIAL, Boston Scientific, Britannia, Intec, Ipsen, Lundbeck, Neuroderm, Neurocrine, Denali Pharmaceuticals, Novartis, Orion Pharma, Prexton,Teva, UCB and Zambon (consultancy and lecture fees in relation to clinical drug development programmes for PD). WP has Royalties in Thieme, Wiley Blackwell, Oxford University Press and Cambridge University Press and has received grant support from MJFF; EU FP7 & Horizon 2020. CG holds a research grant from the VolkswagenStiftung (Freigeist Fellowship), and was supported by the German Parkinson Society, the Deutsche Forschungsgemeinschaft (DFG; GA2031/1–1 and GA2031/1–2) and Actelion Pharmaceuticals. AAK declares that she is on the advisory board of Boston Scientific and Medtronic and has received honoraria from Boston Scientific, Medtronic, Abbott, Teva und Ipsen.
: This manuscript does not contain clinical studies, thus no ethics approval was necessary.
: This manuscript does not contain clinical studies.
: All patients provided written informed consent for publication.